#VTGN
🚨 $VTGN
On November 9, 2026, Vistagen Therapeutics, Inc. announced a regulatory update from its recent, productive Type C meeting with the U.S. Food and Drug Administration to discuss potential registrational paths forward for the development of its lead product candidate, fasedienol, in social a...
SEC Filing: VTGN
Click to view the official SEC document.
www.sec.gov
November 9, 2026 at 1:34 PM
Vistagen #$VTGN marked its Phase 3 PALISADE-3 fasedienol trial as completed on the trial registry.

Mon close $0.17: below SMA50, below SMA200, RSI deeply oversold.

Hub: www.merlintrader.com/vistagen-the...

Not investment advice.
VTGN Stock: Vistagen News, Fasedienol & Funding
Vistagen stock news and analysis: fasedienol nasal spray, the proposed LSAS trial, FDA feedback, Nasdaq compliance, cash and the funding risks for VTGN holders.
www.merlintrader.com
November 3, 2026 at 1:48 PM
🚨 $VTGN
No valid summary extracted.
SEC Filing: VTGN
Click to view the official SEC document.
www.sec.gov
October 30, 2026 at 9:24 PM
#$VTGN weekly close $0.17 (-6.3% w/w), below SMA50 $0.24 / below SMA200 $0.45, RSI 29.5. Support $0.17, resistance $0.28. Broad market sell-off Friday.

New hub updated: www.merlintrader.com/vistagen-the...
October 30, 2026 at 8:57 PM
#$VTGN weekly close $0.17 (-6.3% w/w), below SMA50 $0.24 / below SMA200 $0.45, RSI 29.5. Support $0.17, resistance $0.28. Broad market sell-off Friday.

New hub updated: www.merlintrader.com/vistagen-the...
October 30, 2026 at 8:57 PM
#$VTGN fell 3.7% Friday to $0.18, the low end of its 20-day range ($0.18-$0.32). The 50-day EMA is at $0.26 and the 200-day at $1.08. Daily RSI 31.

Interactive chart at JC Just Charts: justcharts.merlintrader.com#VTGN
Not investment advice.
JustCharts: Stock Charts & Technical Analysis | Merlintrader
Explore US stock charts with EMA 50 and 200, support, resistance, trendlines and conditional technical scenarios. Daily data from the Merlintrader hub universe.
justcharts.merlintrader.com
October 25, 2026 at 12:47 PM
$VTGN Latest company news, October 20, 2026: Vistagen began a collaboration with GATC Health to apply its AI platform to the possible next Phase 3 of fasedienol and other programs. No financial terms disclosed.

https://www.merlintrader.com/vistagen-therapeutics-stock-hub/
Vistagen ($VTGN): Fasedienol After PALISADE, Nasdaq Deadline
Vistagen ($VTGN): what is left of fasedienol after the PALISADE trials, the February 1, 2027 Nasdaq bid-price deadline, cash, dilution and short interest.
www.merlintrader.com
October 20, 2026 at 6:46 PM
Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs
Vistagen (VTGN) has selected GATC Health to apply predictive artificial intelligence across its lead clinical-stage drug development programs.The collaboration brings GATC Health’s Operon platform and Derisq predictive intelligence capabilities to planning for a potential next Phase 3 study of fasedienol for social anxiety disorder. The study would use the Liebowitz Social Anxiety Scale (LSAS) as its primary measure of efficacy. The collaboration also covers potential Phase 2 studies of itruvone for major depressive disorder and refisolone for menopausal hot flashes.Vistagen says it is incorporating predictive insights into fasedienol protocol development alongside its experience and existing datasets. The companies are using predictive modeling to complement traditional development approaches and inform study design, pipeline prioritization and resource allocation.
www.stocktitan.net
October 20, 2026 at 12:30 PM
🚨 $VTGN
Amendment and Restatement of Executive Severance Plan On October 7, 2026, the Board of Directors of Vistagen Therapeutics, Inc. approved an amendment and restatement of the Company’s Change in Control Executive Severance Plan, which was originally adopted effective August 11, 2026 and des...
SEC Filing: VTGN
Click to view the official SEC document.
www.sec.gov
October 10, 2026 at 4:12 AM
🚨 $VTGN
Amendment and Restatement of Executive Severance Plan On October 7, 2026, the Board of Directors of Vistagen Therapeutics, Inc. approved an amendment and restatement of the Company’s Change in Control Executive Severance Plan, which was originally adopted effective August 11, 2026 and des...
SEC Filing: VTGN
Click to view the official SEC document.
www.sec.gov
October 9, 2026 at 9:16 PM
Significant Gains: 8KSpy SEC Filings Realtime Alerts:

https://8KSpy.com

$BENF $VTGN $KXIN $HOWL $TURB

October 8, 2026 at 11:14 AM
Significant Gains: 8KSpy SEC Filings Realtime Alerts:

https://8KSpy.com

$BENF $VTGN $KXIN $HOWL $TURB

October 7, 2026 at 1:52 PM
Fasedienol after PALISADE-4, plus a Nasdaq deadline. What is left:

Vistagen Therapeutics (#$VTGN): What Is Left of Fasedienol After PALISADE-4, and What Happens Before February 1, 2027?

What to watch: www.merlintrader.com/vistagen-the...
October 4, 2026 at 9:02 PM
Scorecard updated for VTGN (VTGN). Score: 67/100 (Bullish Setup). Stance: Selective Accumulation. #VTGN
September 30, 2026 at 5:32 PM
$VTGN — Press Release

Vistagen Therapeutics, Inc. filed an 8-K on September 25, 2026, disclosing that it began utilizing a new corporate presentation (Exhibit 99.1) under Regulation FD.

🧵 continued ↓
September 25, 2026 at 2:47 PM
🚨 $VTGN
On September 25, 2026, Vistagen Therapeutics, Inc. began utilizing a new corporate presentation, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1. The information under this Item 7.01 and Exhibit 99.1 attached hereto are intended to be furnished and shall not...
SEC Filing: VTGN
Click to view the official SEC document.
www.sec.gov
September 25, 2026 at 1:12 PM
👁️ #$ONCO +45%! SRX Global (#$SRXH) dumps VTGN + #$GRML, buys Onconetix — betting on its Realbotix acquisition: patented robot EYEBALLS with Vinci AI vision (facial recognition, drones, body cams). $5.1M cap, 26.8M volume on 3.95M shares — low-float rocket. ⚠️ Acquisition NOT closed, -$10.2M income.
September 25, 2026 at 2:00 PM
Look at these Significant Gains on 8KSpy SEC Filings Realtime Alerts:

https://8KSpy.com

$BENF $VTGN $KXIN $HOWL $TURB

[img]DDAmanda.com/Charts/...]
September 24, 2026 at 8:26 PM
🚨 $VTGN
On September 24, 2026, Vistagen Therapeutics, Inc. issued a press release summarizing positive exploratory efficacy data presented by the Company at Psych Congress 2026. The poster highlights a potential efficacy signal for fasedienol nasal spray, the Company's rapid-onset Phase 3 product...
SEC Filing: VTGN
Click to view the official SEC document.
www.sec.gov
September 24, 2026 at 11:31 AM
Vistagen (#$VTGN) presents exploratory data showing fasedienol had a statistically significant benefit in a "very severe" social anxiety subgroup of PALISADE-4, even though the overall Phase 3 trial missed its primary endpoint. Post-hoc finding, not confirmatory.

prismmarketview.com/vistagen-hig...
September 24, 2026 at 1:35 PM
$VTGN — Vistagen Therapeutics' Fasedienol drug trial results and significant revenue growth contrasted with overbought technical indicators.

On the upside: Year-over-year quarterly revenue growth of 504.9%.

https://market-scanner.net/tickers/VTGN.US

#ai #trading
VTGN.US — AI analysis summary
Descriptive, non-directional summary of recent AI analyses.
market-scanner.net
September 24, 2026 at 12:31 PM
NASDAQ Top 3 most-shorted Stocks (based on Shorted Share Volume not Dollar Value): $VTGN 128,069,408 shares | $GCDT 69,285,037 shares | $BFRG 56,655,398 shares | 2026-09-23
September 23, 2026 at 11:57 PM